Topic:
M&A
Latest Headlines
Latest Headlines
OPKO Health to acquire Prolor Biotech for $480M
OPKO Health announced today that it is poised to acquire Israel-based Prolor Biotech in an all-stock transaction valued at $480 million, or $7 per share of Prolor common stock.
Moody's: Deep-pocketed pharma giants poised to boost M&A activity this year
Here's a multibillion-dollar question: With their improved cash positions, will pharma companies increase spending this year on acquisitions? Over at Moody's, analysts predict that the answer to this question will be "yes" and deep-pocketed pharma companies will spend big dollars on M&A deals.
Drugmakers, get ready for bigger, faster dealmaking, Moody's says
Deal junkies, rejoice. Moody's Investors Service figures pharma M&A will pick up in 2013, after a not-so-exciting 2012. But even if the pace picks up, deal size probably won't increase much; we're looking at another year of small- to medium-sized buyouts, rather than megamergers.
Elan spurns buyout offer, preps for deal spree
Elan's board of directors has rejected an $11.25-per-share bid by Royalty Pharma, and some analysts say that at this point there's not much likelihood that Royalty can win out in the end.
Quintiles' revenue jumps 4.2% in Q1
Quintiles pulled in $927 million in revenue last quarter, a 4.2% jump over the same period last year the CRO attributes in part to 2012's many acquisitions.
Russia tells Abbott no-go on buyout of partner Petrovax
Abbott Laboratories wanted to buy out its vaccine partner in Russia to better establish itself there. But the Russian government has not exactly thrown its arms open to Big Pharma and Abbott's hope has now been dashed on the hard wall of that reality.
Russian regulators nix Abbott's M&A plans
Abbott Laboratories made a bid to acquire Russian vaccine outfit Petrovax, but the country's Federal Anti-Monopoly Service denied scuttled its plan.
Johnson & Johnson cashes out on Elan shares after failed Alzheimer's trials
Johnson & Johnson has sold 82 million Elan shares for $11.25 per share as part of Elan's $1 billion stock buyback plan, providing J&J's Janssen unit an after-tax gain of $213 million. The "Dutch Auction" price for Elan's buyback has implication for Royalty Pharma's ongoing efforts to acquire the Ireland-based biotech for up to $7.3 billion.
Siemens selling Alzheimer's Dx agents to Lilly
Eli Lilly plans to buy two of Seimens Healthcare Alzheimer's imaging agents, used in PET scans, all part of the drugmaker's shifting approach to treating the disease.
At long last, Sony and Olympus launch medical device joint venture
After indefinitely suspending their plans over a Chinese regulatory snag, Sony and Olympus are finally kicking off their long-planned medical device joint venture, planning to sell endoscopes and imaging technologies around the world.
